Journal
NANOSCALE RESEARCH LETTERS
Volume 11, Issue -, Pages -Publisher
SPRINGER
DOI: 10.1186/s11671-016-1599-y
Keywords
Self-targeted multi-drug co-delivery system; 10-Hydroxycamptothecin; Methotrexate; Controlled and sustained release
Funding
- Natural Science Foundation of China [21502007]
- Natural Science Foundation of Fujian Province of China [2016J01406]
- Fujian Province medical innovation project [2014-CX-35]
- science and technology personnel training project Xinjiang Uygur Autonomous Region of China [qn2015bs014]
Ask authors/readers for more resources
We developed a novel self-targeted multi-drug co-delivery system based on rod-shaped 10-hydroxycamptothecin (CPT) nanoanticancer drug (CPT NRs) followed by a surface functionalization with self-targeting PEGylated lipid-conjugated methotrexate (MTX) pro-anticancer drug. The self-targeting effect and in vitro cell viability of the MTX-PEG-CPT NRs on HeLa cells were demonstrated by comparative cellular uptake and MTT assay of the PEG-CPT NRs. In vitro studies showed the feasibility of using this high drug-loading MTX-PEG-CPT NRs in self-targeted drug delivery, controlled-/sustained-release, and synergistic cancer therapy. More importantly, this work would stimulate interest in the use of PEGylated lipid-conjugated MTX by introducing an early-phase tumor-targeting role and then driving a late-phase anticancer role for the highly convergent design of nanomulti-drug, which may advantageously offer a new and simple strategy for simultaneously targeting and treating FA receptor-overexpressing cancer cells.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available